Levtock 750mg Tablet contains Levetiracetam, an antiepileptic agent indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure propagation. This medication is typically prescribed as adjunctive therapy in adults and pediatric patients aged one month and older. Levtock 750mg is administered orally, with dosage individualized based on patient response and clinical condition. Common adverse effects may include somnolence, dizziness, fatigue, irritability, and headache, which are generally mild to moderate in severity. Caution is advised in patients with renal impairment, as dosage adjustment may be necessary. Levtiracetam has a favorable pharmacokinetic profile characterized by rapid absorption, minimal protein binding, and predominant renal excretion. It is important to adhere to prescribed dosing schedules to maintain therapeutic plasma concentrations and reduce the risk of breakthrough seizures. Patients should be monitored regularly for efficacy and potential side effects, and any signs of mood changes or behavioral disturbances should be promptly reported to a healthcare professional. Levtock 750mg Tablet should be used under strict medical supervision.